ACOX1 and Hepatic steatosis: In conclusion, we showed that a novel treatment with a combination of LC and NR, but not the mono-treatments, significantly attenuated obesity, fat mass, hepatic steatosis and exerted beneficial effects on metabolic control pathways and upstream regulators (ACOX, SCPAP, SREBF2, PPARGC1B, INSR) in the liver.